Search
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid
Talquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalon July 21, 2023. … [L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells.
Synonyms: ANTIBODY; BISPECIFIC GAMMA4 HEAVY CHAIN HUMANIZED AN, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONALClonidine
go.drugbank.com/drugs/DB00575ApprovedInvestigational[L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237] … Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.
Categories: Sympathomimetics in Glaucoma TherapySynonyms: 2,6-Dichloro-N-2-imidazolidinylidenebenzenamineMiltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalIt can be administered topically or orally and is only indicated in patients aged 12 years or older. … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalIt was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.
Leflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. … Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Synonyms: 4-ISOXAZOLECARBOXAMIDE, 5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamideProducts: Nu-leflunomideChloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigationalSimilar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. … [L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration, similar to the one observed with [lidocaine].
Categories: Esters of Aminobenzoic AcidMagnesium acetate
go.drugbank.com/drugs/DB13996ApprovedSynonyms: acetato de magnesio, Magnesium di(acetate)Mixtures: ELETTROLITICA BILANCIATA DI MANTENIMENTO CON GLUCOSIO BAXTER, ELETTROLITICA BILANCIATA DI MANTENIMENTO CON GLUCOSIO BAXTERAmsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. … It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.
Categories: Compounds used in a research, industrial, or household settingInternational brands: AMSA P-DOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. … by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of
Categories: combinations of tetracyclines